Open AccessEarly Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis
Author(s) -
Ju Sang Kim,
Yong-hyun Kim,
Sang Haak Lee,
Yee Hyung Kim,
Jin-Woo Kim,
Ji Young Kang,
Sung Kyoung Kim,
Seung Joon Kim,
Yun-Seong Kang,
Tae-hyung Kim,
Jeongha Mok,
Min Kwang Byun,
Hye Jung Park,
Joon Sung Joh,
Yong Bum Park,
HyeongSeok Lim,
Hong-Jo Choi,
Seung Heon Lee,
Hye-Jin Kim,
Jeongseong Yang,
Hyunji Kim,
Xianlin Shen,
Abdullah Alsultan,
Insook Cho,
Lawrence Geiter,
Tae Sun Shim
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01684-21
Subject(s) - ethambutol , medicine , pyrazinamide , isoniazid , linezolid , rifampicin , antibacterial agent , tuberculosis , gastroenterology , adverse effect , microbiology and biotechnology , antibiotics , pharmacology , bacteria , biology , staphylococcus aureus , pathology , vancomycin , genetics
Delpazolid, an oxazolidinone, has been studied in non-clinical studies of efficacy and toxicity and Phase 1 clinical studies. Delpazolid hasin vitro activity against Gram-positive bacteria, includingMycobacterium tuberculosis .